recenti topic issues dalla letteratura non br br onj dr
play

Recenti TOPIC-ISSUES dalla letteratura non-BR BR-ONJ DR. PAOLO G. - PowerPoint PPT Presentation

Recenti TOPIC-ISSUES dalla letteratura non-BR BR-ONJ DR. PAOLO G. ARDUINO, DDS, MSC, PHD SCUOLA DI MEDICINA DIPARTIMENTO DI SCIENZE CHIRURGICHE UNIVERSITA DEGLI STUDI DI TORINO CIR DENTAL SCHOOL Jaw osteonecrosis. . When did it it


  1. Recenti TOPIC-ISSUES dalla letteratura non-BR BR-ONJ DR. PAOLO G. ARDUINO, DDS, MSC, PHD SCUOLA DI MEDICINA – DIPARTIMENTO DI SCIENZE CHIRURGICHE UNIVERSITA’ DEGLI STUDI DI TORINO – CIR DENTAL SCHOOL

  2. Jaw osteonecrosis. . When did it it start?

  3. BRONJ 2003

  4. BRONJ 2003

  5. Bisphosphonates-related Osteonecrosis of the Jaw

  6. MRONJ 2014

  7. Medication-related Osteonecrosis of the Jaw

  8. MRONJ _ definition

  9. MRONJ (medication?)

  10. MRONJ (medication?)

  11. 2014  2018 1. 1. LITERATURE REVIEW (non-BR-ONJ)

  12. 2014-2018 (march)

  13. 2014-2018 (march)

  14. 2014-2018 (march)

  15. 2014-2018 (march)

  16. 2014-2018 (march)

  17. 2014-2018 (21st of April) - Denosumab - Rituximab - Bevacizumab - Imatinib - Sunitinib - Adalimumab - Aflibercept - Regorafenib - Axitinib - Sorafenib - Everolimus - Ipilimumab - Methotrexate - Cabozantinib - Imatinib - Romosozumab - Raloxifene - Infliximab - Erlotinib - Dasatinib

  18. 2014-2018 Rituximab  a.CD20 - De Denosu sumab - Bevacizumab  a.a.g. Imatinib  i.RTK - - Sunitinib  i.RTK Adalimumab  a.TNF - - Aflibercept  a.a.g. Regorafenib  i.RTK - - Axitinib  i.RTK Sorafenib  a.FAK - - Everolimus  i.mTOR Ipilimumab  anti-CTLA-4 - - Methotrexate  i.s. Cabozantinib  i.RTK - - Imatinib  i.RTK Romosozumab  s.m.a. - - Raloxifene  SERMs Regorafenib  a.a.g. - - Infliximab  a.TNF - Erlotinib  i.RTK - Dasatinib  i.RTK -

  19. MRONJ _ incidence

  20. MRONJ _ incidence

  21. non-BR BR-ONJ _ incidence worldwide

  22. non-BR BR-ONJ _ incidence - 1 case per 666 cancer patients treated - 1 case per 10.000 osteoporotic patients

  23. non-BR BR-ONJ _ incidence Piedmont

  24. non-BR BR-ONJ _ difference with BRONJ?

  25. non-BR BR-ONJ _ difference with BRONJ? - No difference in comorbidities

  26. non-BR BR-ONJ _ difference with BRONJ? - No clinical differences

  27. non-BR BR-ONJ _ difference with BRONJ? - No radiological differences

  28. non-BR BR-ONJ _ difference with BRONJ?

  29. non-BR BR-ONJ _ difference with BRONJ? - Prevention differences?

  30. non-BR BR-ONJ _ difference with BRONJ?

  31. non-BR BR-ONJ _ difference with BRONJ?

  32. non-BR BR-ONJ _ difference with BRONJ? - Outcome differences?

  33. non-BR BR-ONJ _ Take home message

  34. non-BR BR-ONJ _ Take home message - Denosumab, bevacizumab, sunitinib - < incidence - Probably differences in the duration of therapy (no dose cumulative) - Probably better surgical outcome (no data on medical one) Difficulties in the correct classification (  ) and nomenclature - - New other drugs ? …. incoming

Recommend


More recommend